Videos

Experts in neurology review the recent approvals of pitolisant and solriamfetol for the management of excessive daytime sleepiness (EDS) and compare their mechanisms of action.

The duo from Montefiore Medical Center detailed the reasons why EEGs must remain an interictal part in improving rates of misdiagnosing neonatal seizures.

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.

Neurology News Network for the week ending March 27, 2021.

The director and founder of the Sleep Centers of Middle Tennessee discussed the misleading nature of the term ‘sleep apnea.’

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine outlined the Florida Stroke Registry and its capabilities.

Panelists suggest how to differentiate between diabetic neuropathy and ATTR amyloidosis.

Understanding the diagnostic process in making a ATTR amyloidosis diagnosis.

The director of the Montefiore Headache Center discussed recent advances in treating migraine both acutely and preventively.

The senior investigator at the National Institutes of Neurological Disorders and Stroke outlined studies on anakinra and tolebrutinib as part of a new phase 2a clinical trial paradigm.

A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.

The Neuroimmunology Clinical Fellow at the National Institutes of Health discussed the evaluations of 2 therapies in multiple sclerosis that she is partaking in.

The postdoctoral researcher at Columbia University discussed ways clinicians and patients with multiple sclerosis can take to ease the transition of disclosing their diagnosis.

Types of foods and weather conditions that may trigger migraine attacks.

Recommendations for incorporating and adhering to lifestyle interventions that can help prevent migraine or reduce the severity of attacks.

Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.

The neurologist from the University of Washington Medical Center discussed the findings of her recent study presented at ACTRIMS Forum 2021.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed how patient feedback can positively impact the direction of dementia research.

Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).

Experts remind families of the importance of follow-up visits with the multidisciplinary team during COVID-19.

Resources are discussed, including the Child Neurology Foundation’s telehealth tip sheet, to help families navigate telehealth.

Several spinal muscular atrophy (SMA) resources are suggested to help physicians and families, including Cure SMA and standard of care guidelines.

Discussing the diagnosis of spinal muscular atrophy (SMA) with the family and lining up appointments with the multidisciplinary team to help care for the patient.

Diana Castro, M.D., stresses the value of the initial in-person neurology visit for evaluation of spinal muscular atrophy (SMA) to ensure a correct diagnosis. The next step in the process would be genetic testing.

The signs and symptoms leading a pediatrician to a diagnosis of spinal muscular atrophy (SMA) are discussed.

Key opinion leaders discuss pharmacotherapeutic options for the management of narcolepsy symptoms and examine the safety and efficacy of potential treatments.

Experts in neurology discuss the goals of treatment and consider behavioral approaches to the management of narcolepsy and idiopathic hypersomnia including naps and exposure to sunlight.

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

The chief scientific officer of the Parkinson’s Foundation discussed the “PD GENEration” study that offers genetic testing and counseling to 15,000 people with Parkinson disease.

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.